High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

F. Zwierenga; B. A. M. H. van Veggel; L. E. L. Hendriks; T. J. N. Hiltermann; B. I. Hiddinga; L. B. M. Hijmering-Kappelle; A-M. C. Dingemans; C. van der Leest; A. J. de langen; M. van den Heuvel; A. J. van der Wekken

doi:10.1016/j.annonc.2021.08.1819

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20

F. Zwierenga, B. A. M. H. van Veggel, L. E. L. Hendriks, T. J. N. Hiltermann, B. I. Hiddinga, L. B. M. Hijmering-Kappelle, A-M. C. Dingemans, C. van der Leest, A. J. de langen, M. van den Heuvel, A. J. van der Wekken

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S966-S966
Number of pages	1
Journal	Annals of Oncology
Volume	32
Issue number	S5
DOIs	https://doi.org/10.1016/j.annonc.2021.08.1819
Publication status	Published - 2021
Event	Congress of the European-Society-for-Medical-Oncology (ESMO) - Duration: 16-Sept-2021 → 21-Sept-2021

Access to Document

10.1016/j.annonc.2021.08.1819

Handle.net

Persistent link

Cite this

Zwierenga, F., van Veggel, B. A. M. H., Hendriks, L. E. L., Hiltermann, T. J. N., Hiddinga, B. I., Hijmering-Kappelle, L. B. M., Dingemans, A.-M. C., van der Leest, C., de langen, A. J., van den Heuvel, M., & van der Wekken, A. J. (2021). High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20. Annals of Oncology, 32(S5), S966-S966. https://doi.org/10.1016/j.annonc.2021.08.1819

@article{aa401cac576b45d2a22250f298220608,

title = "High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20",

author = "F. Zwierenga and {van Veggel}, {B. A. M. H.} and Hendriks, {L. E. L.} and Hiltermann, {T. J. N.} and Hiddinga, {B. I.} and Hijmering-Kappelle, {L. B. M.} and Dingemans, {A-M. C.} and {van der Leest}, C. and {de langen}, {A. J.} and {van den Heuvel}, M. and {van der Wekken}, {A. J.}",

year = "2021",

doi = "10.1016/j.annonc.2021.08.1819",

language = "English",

volume = "32",

pages = "S966--S966",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "S5",

note = "Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 16-09-2021 Through 21-09-2021",

}

Zwierenga, F, van Veggel, BAMH, Hendriks, LEL, Hiltermann, TJN , Hiddinga, BI , Hijmering-Kappelle, LBM, Dingemans, A-MC, van der Leest, C, de langen, AJ, van den Heuvel, M & van der Wekken, AJ 2021, 'High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20', Annals of Oncology, vol. 32, no. S5, pp. S966-S966. https://doi.org/10.1016/j.annonc.2021.08.1819

TY - JOUR

T1 - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC

T2 - Congress of the European-Society-for-Medical-Oncology (ESMO)

AU - Zwierenga, F.

AU - van Veggel, B. A. M. H.

AU - Hendriks, L. E. L.

AU - Hiltermann, T. J. N.

AU - Hiddinga, B. I.

AU - Hijmering-Kappelle, L. B. M.

AU - Dingemans, A-M. C.

AU - van der Leest, C.

AU - de langen, A. J.

AU - van den Heuvel, M.

AU - van der Wekken, A. J.

PY - 2021

Y1 - 2021

U2 - 10.1016/j.annonc.2021.08.1819

DO - 10.1016/j.annonc.2021.08.1819

M3 - Meeting Abstract

SN - 0923-7534

VL - 32

SP - S966-S966

JO - Annals of Oncology

JF - Annals of Oncology

IS - S5

Y2 - 16 September 2021 through 21 September 2021

ER -